US Patent 8,552,025: Scope, Claim Architecture, and US Landscape for Methylnaltrexone Stable Acidic Parenteral Solutions

US 8,552,025 claims a narrow but commercially relevant formulation space: a stable methylnaltrexone (or salt) aqueous solution maintained at an acidic pH window (3.0 to 4.0, with dependent ranges down to about 3.0 to 3.5 and specific embodiments at about 3.0, about 3.5). Claim protection is anchored to (1) pH control, (2) drug concentration ranges, (3) stability time at “about room temperature” (6, 12, or 24 months), and (4) parenteral suitability, including container formats (vial with septum or syringe) and optional excipients (preservatives and isotonicity agents). This makes the patent strongest against direct formulation work that preserves the same physicochemical target profile.

Because only the independent claim 1 (and claim 18’s additional aggregation) is provided, the analysis below treats the provided claims as the operative claim set and focuses on scope and likely infringement/avoidance vectors within the US formulation landscape.

What does claim 1 actually protect?

Claim 1 defines a composition-level product-by-parameters:

Active: methylnaltrexone or a salt thereof
Form: stable pharmaceutical preparation comprising a solution (implies aqueous solution unless further limited elsewhere)
Critical parameter 1: pH about 3.0 to about 4.0
Stability: “stable pharmaceutical preparation” is used, but the explicit stability durations appear in dependent claims 6-8 (6, 12, 24 months at about room temperature). The term “stable” in claim 1 still captures preparations that meet the stability concept used throughout the patent.

Scope implications of claim 1

This claim does not recite specific:

buffer systems,
specific preservative molecules,
isotonicity agent identity,
vehicle composition (aside from being a solution),
concentration (handled in dependent claims 3-5),
packaging (handled in claim 14),
or administration route (handled in claims 13-17).

That omission matters. It means claim 1 can cover multiple excipient packages as long as the pH window and “stable pharmaceutical preparation” requirement are satisfied.

Which dependent claims narrow the protected space?

pH narrowing

The dependent claim ladder tightens the pH window:

Claim 2: pH about 3.0 to about 3.5
Claim 21: pH about 3.5
Claim 22: pH about 3.0 to about 3.5 (duplicate scope refinement)
Claim 23: pH about 3.5 (duplicate refinement)

Concentration narrowing

Claim 3: methylnaltrexone concentration 0.01 to 100 mg/mL
Claim 4: concentration 1.0 to 50.0 mg/mL
Claim 5: concentration about 20 mg/mL

These dependent claims are important for design-around. If a competitor stays within the same pH window but moves concentration outside the dependent ranges, they may still fall into claim 1 (because claim 1 itself does not constrain concentration). Still, claim 3-5 can matter for validity and enforcement because they define concrete embodiments.

Stability-duration narrowing

Claim 6: stable to storage 6 months at about room temperature
Claim 7: stable to storage 12 months at about room temperature
Claim 8: stable to storage 24 months at about room temperature

If a product meets the pH window but cannot demonstrate the stability duration used in the dependent claims, infringement of claim 6-8 may be avoidable, but claim 1 can still remain in play because claim 1 does not lock the specific duration.

Excipient optionality

Optional components are not mandatory but expand coverage when present:

Preservative: claims 9, 10, 15 (depending on which base claim they attach to)
Isotonicity agent: claims 11, 12, 16

These are drafted broadly: they do not recite which preservative or which isotonicity agent.

Parenteral and container format

Claim 13: suitable for parenteral administration
Claim 14: solution provided in a vial with a septum or a syringe
Claims 17: parenteral administration tied to claim 6

The vehicle does not need to be restricted to a specific route other than “parenteral administration,” which often covers SC/IV/IM. Claim 14 is a practical packaging limiter.

What is claim 18 adding beyond claim 1?

Claim 18 is an aggregation claim that requires multiple features simultaneously:

pH 3.0 to 4.0
stable to storage 6 months at about room temperature
suitable for parenteral administration
and the preparation comprises methylnaltrexone or a salt as a solution

Scope effect

Claim 18 is narrower than claim 1 because it requires all of the above. It becomes a stronger litigation claim when accused products clearly match: 1) pH range,
2) stability-duration performance, and
3) parenteral use.

Dependent claims 19-23 then add preservative/isotonicity and tighter pH endpoints again.

Infringement map: what would likely trigger coverage?

Below is a feature-to-claim linkage model based strictly on the provided claims.

Product feature	Matches which claim elements
Methylnaltrexone (or salt) in aqueous solution	Claim 1, 18 base structure
pH maintained between ~3.0 and ~4.0	Claim 1, 18, 2-3/21-23 refinements
pH maintained between ~3.0 and ~3.5	Claim 2, 18 via claim 18 + claim 22; and claim 21/23
Concentration within 0.01-100 mg/mL	Claim 3 (but does not appear required by claim 1)
Concentration within 1.0-50 mg/mL	Claim 4
Concentration about 20 mg/mL	Claim 5
Stability at room temperature for 6 months	Claim 6; also claim 18
Stability at room temperature for 12 months	Claim 7
Stability at room temperature for 24 months	Claim 8
Parenteral suitability	Claim 13; also claim 18
Vial with septum or syringe	Claim 14
Includes preservative	Claims 9/10/15/19
Includes isotonicity agent	Claims 11/12/16/20

Practical enforcement posture

The broadest “first strike” theory is claim 1. The strongest product-comparison theory is claim 18 if the accused product’s formulation package hits:

the pH window,
room-temperature stability duration,
and parenteral use.

Claim construction pressure points (where design-arounds succeed or fail)

Even without the full specification, the claim language sets clear pressure points:

1) The pH window is the core barrier

Claim 1 is “between about 3.0 and about 4.0.”
Dependent claims focus on “about 3.0 to about 3.5” and “about 3.5.”

Design-around tends to require moving outside the claimed pH range. If a competitor keeps pH at 4.05 vs 3.95, they aim to avoid claim 1’s window; if pH lands within 3.0 to 4.0, they stay exposed.

2) Stability duration matters for claim 18 and claims 6-8

Claim 1 still uses the word “stable,” but the dependent claims tie directly to “stable to storage for 6/12/24 months at about room temperature.” Those are measurable and typically contested.

If a competitor demonstrates instability or reduced stability at the claimed room-temperature duration, they may avoid claim 6-8 and claim 18 while still potentially risking claim 1.

3) Concentration is not limiting in claim 1

Concentration ranges exist only in dependent claims (3-5). That means:

moving concentration outside 1-50 mg/mL may avoid claims 4-5 but not necessarily claim 1.

4) Preservatives/isotonicity are optional

Excipients are not required by claim 1. They extend coverage if included, but their presence is not a gating feature for the main pH-based claim.

5) Packaging limits exist only in claim 14

If a product uses the same formulation but different device/container, they could avoid claim 14 while remaining within claim 1 and 18.

What is the likely “patent landscape” shape in the US?

Given only the claims, the landscape analysis below is framed as a US competitive taxonomy: who is likely to be blocked and how.

Landscape axis A: acidified solution formulations

This patent targets a specific formulation strategy: acidic pH to maintain solution stability for methylnaltrexone parenteral use.

Likely at-risk entrants

Any manufacturer developing a methylnaltrexone parenteral solution that maintains pH within ~3.0 to ~4.0 and shows room-temperature stability.
Any reformulation that changes buffer chemistry or excipient identity but keeps the same pH and stability envelope.

Likely lower-risk entrants

Formulations operating outside the pH window (above about 4.0 or below about 3.0), assuming the stability is maintained through other mechanisms.
Solid dosage or non-solution delivery systems (not covered by “comprising a solution” language).
Solutions that lack the “stable” property or cannot meet the room-temperature stability durations where relevant to claim 18.

Landscape axis B: parenteral-ready liquid products

The patent includes “suitable for parenteral administration.” That captures injectable solutions generally, without limiting to a single route in the provided claims.

Landscape axis C: excipient package variations

Because preservatives/isotonicity agents are optional, excipient substitution alone is not a strong design-around. Competitors typically must alter pH or stability outcome.

Scope summary: claim strength and practical coverage

Broadest claim

Claim 1 is the broadest because it requires only the pH window and solution structure.

Most enforceable dependent “combo” claim

Claim 18 is a strong enforcement anchor because it aggregates pH, 6-month room temperature stability, and parenteral suitability.

Most specific embodiment claims

Claim 5 fixes concentration at about 20 mg/mL.
Claim 21/23 fix pH at about 3.5.
Claim 14 fixes container format (septum vial or syringe).

Key Takeaways

US 8,552,025 protects methylnaltrexone (or salts) aqueous stable parenteral solutions defined mainly by pH about 3.0 to about 4.0.
Dependent claims narrow to pH ~3.0 to ~3.5, pH about 3.5, and specific concentration bands (including about 20 mg/mL).
The most litigation-relevant performance hook is room-temperature stability for 6 months (claim 18), reinforced by separate 6/12/24-month dependent claims.
Preservatives and isotonicity agents do not need to be present to infringe claim 1, and container choice does not control claim 1 exposure (only claim 14).
Design-around most plausibly requires moving the formulation outside the 3.0 to 4.0 pH window and/or changing stability outcomes tied to the 6-month room-temperature requirement.

FAQs

1) What is the single most important parameter in US 8,552,025?

The formulation pH. Claim 1 and claim 18 both hinge on pH about 3.0 to about 4.0.

2) Does the patent require a specific preservative?

No. Preservatives appear in dependent claims (e.g., claims 9/10/15/19), so claim 1 can be infringed without a preservative.

3) Can a product avoid the patent by changing concentration?

Concentration is only limited in dependent claims (claims 3-5). Changing concentration may avoid those dependent claims but does not avoid claim 1 unless the pH and stability elements fall outside the claim.

4) Which claim is strongest for enforcement if stability data are available?

Claim 18, because it requires pH 3.0-4.0, 6 months stability at about room temperature, and parenteral suitability in one claim.

5) Does packaging matter?

Only for claim 14, which targets “a vial with a septum or in a syringe.” Packaging does not appear to be required for claim 1.

References

[1] US Patent 8,552,025, claims 1-23 (methylnaltrexone stable acidic pharmaceutical solutions; pH 3.0-4.0; room-temperature stability; parenteral suitability).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004229463	⤷ Start Trial
Australia	2010202824	⤷ Start Trial
Australia	2013203378	⤷ Start Trial
Brazil	PI0409133	⤷ Start Trial
Canada	2521379	⤷ Start Trial
Canada	2811272	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,552,025

Summary for Patent: 8,552,025